Monitoring the intrahepatic immune responses in chronic HBV patients after long-term treatment with tenofovir
Recruiting
- Conditions
- chronic hepatitis B1001965410047438
- Registration Number
- NL-OMON41768
- Lead Sponsor
- Stichting Maag-, Darm- en Leveronderzoek
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 10
Inclusion Criteria
* Chronic HBV patients who were included in the Tenofovir-FNAB study, and are currently still under treatment with tenofovir or became HBsAg-negative (HBsAg loss) in the meantime
* Signed informed consent
Exclusion Criteria
* (Re-) infection with HIV, hepatitis B or C after the Tenofovir-FNAB study * Decompensatedcirrhosis (Child * Pugh Grade B or C) * Ultrasonic or other prove of hepatocellular
carcinoma or other carcinoma * Pregnant woman * Any other condition or
prescribed medication in which in the opinion of the investigator would make the
patient unsuitable for enrollment.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Frequency, phenotype and function of intrahepatic and peripheral NK cells</p><br>
- Secondary Outcome Measures
Name Time Method <p>N.A.</p><br>